Physician profile
John C Shipp
NPI 1801027453
$3,080.41
in general payments reported to CMS, 2019-2025
28 companies · $693 in 2025
The $693 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $618 · 2023: $759 · 2024: $701 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $418.56 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $245.17 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.23 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $189.67 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $186.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $103.49 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $87.57 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Janssen Pharmaceuticals, INC | $80.03 | 2021-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.26 | 2025 | Caplyta |
| Organon LLC | $70.55 | 2021-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $69.04 | 2023-2025 | Steglatro, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $65.09 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $60.27 | 2021-2024 | |
| Phadia US INC. | $59.56 | 2024 | Immunocap |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $55.51 | 2025 | |
| Nestle Healthcare Nutrition INC. | $53.41 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $34.45 | 2023 | Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2024 | |
| Phathom Pharmaceuticals, INC. | $26.14 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $22.61 | 2023 | Glassia |
| Cranial Technologies, INC | $21.82 | 2023 | Doc Band |
| Amgen INC. | $18.78 | 2024 | Otezla, Repatha |
| Mylan Specialty L.P. | $17.97 | 2023 | Yupelri |
| Hologic Sales and Service, LLC | $17.82 | 2023 | Aptima |
| Exact Sciences Corporation | $14.38 | 2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $14.30 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.